Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Here's context current as of this review
The most frequent adverse events were mainly mild-to-moderate gastrointestinal events, which reduced over time."The magnitude of weight loss observed with retatrutide has the potential to slow disease progression and reshape how we treat and manage type 2 diabetes," Bajaj said in a statement.Several authors disclosed ties to biopharmaceutical companies, including Eli Lilly, which is developing retatrutide and funded the study.Abstract/Full Text (subscription or payment may be required)More Information.Sign up for our weekly HealthDay newsletter
See Your Options Did You Know
J Mol Biol 2004
US$ 29.53
US$ 22.37
US$ 23.15
US$ 24.50
US$ 23.59
US$ 22.20
US$ 22.67
